Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

E M C Driessen; P de Lorenzo; M Campbell; M Felice; A Ferster; I Hann; A Vora; L Hovi; G Escherich; C K Li; G Mann; T Leblanc; F Locatelli; A Biondi; J Rubnitz; M Schrappe; L Silverman; J Stary; R Suppiah; T Szczepanski; M Valsecchi; R Pieters

doi:10.1038/leu.2015.246

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

Leukemia. 2016 May;30(5):1184-7. doi: 10.1038/leu.2015.246. Epub 2015 Sep 15.

Authors

E M C Driessen¹, P de Lorenzo², M Campbell³, M Felice⁴, A Ferster⁵, I Hann⁶, A Vora⁷, L Hovi⁸, G Escherich⁹, C K Li¹⁰, G Mann¹¹, T Leblanc¹², F Locatelli¹³, A Biondi¹³, J Rubnitz¹⁴, M Schrappe¹⁵, L Silverman¹⁶, J Stary¹⁷, R Suppiah¹⁸, T Szczepanski¹⁹, M Valsecchi², R Pieters^{1

20

21}

Affiliations

¹ Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
² Interfant-99 Trial Data Center, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.
³ Chilean National Pediatric Oncology Group, PINDA, Roberto del Rio Hospital, Universidad de Chile, Santiago, Chile.
⁴ Department of Pediatric Hematology/Oncology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina.
⁵ Department of Hemato-Oncology, Hôpital Unviversitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium.
⁶ UK Children's Cancer Study Group, Great Ormond Street Hospital for Children, London, UK.
⁷ Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK.
⁸ Nordic Society of Paediatric Haematology and Oncology, University of Helsinki, Helsinki, Finland.
⁹ University Medical Center Hamburg-Eppendorf, Clinic of Pediatric Hematology and Oncology, Hamburg, Germany.
¹⁰ Hong Kong Paediatric Haematology and Oncology Study Group, Prince of Wales Hospital, Hong Kong, China.
¹¹ St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital, Department of Pediatrics, Medical University School, Vienna, Austria.
¹² Departement of Pediatric Hematology, Hôpital Robert-Debré, Paris, fort he FRALLE group, Paris, France.
¹³ Associazione Italiana Ematologia Oncologia Pediatrica, Italy Bambino Gesù Children's Hospital, Rome, Italy.
¹⁴ St Jude Children's Research Hospital, Memphis, TN, USA.
¹⁵ Berlin-Frankfurt-Münster Study Group, Hannover, Germany.
¹⁶ Dana-Farber Cancer Institute ALL Consortium, Boston, MA, USA.
¹⁷ Czech Pediatric Haematology, Prague, Czech Republic.
¹⁸ Australian and New Zealand Children's Haematology and Oncology Study Group, North Adelaide, Australia.
¹⁹ Polish Pediatric Leukemia and Lymphoma Study Group, and Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland.
²⁰ Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
²¹ Dutch Childhood Oncology Group, The Hague, the Netherlands.

PMID: 26369984
DOI: 10.1038/leu.2015.246

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Humans
Infant
Infant, Newborn
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
Recurrence
Treatment Outcome

Grants and funding

15958/CRUK_/Cancer Research UK/United Kingdom